A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This randomized, open-label, two-way crossover study will evaluate the relative
bioavailabilty and safety of capecitabine rapid disintegrating tablets (RDT) versus
commercial Xeloda tablets in patients with colorectal or breast cancer. Patients will be
randomized to a sequence of single oral doses of capecitabine RDT or Xeloda on Days 1 and 2
of a 14-day treatment cycle with Xeloda. Follow-up will be 30 days.